SEARCH

SEARCH BY CITATION

References

  • 1
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention Detection, Evaluation and Treatment of High Blood Pressure. JAMA. 2003;289:25602572.
  • 2
    Garg JP, Elliott WJ, Folker A, et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18:619626.
  • 3
    Rose AJ, Berlowitz DR, Orner MB, et al. Understanding uncontrolled hypertension: is it the patient or provider? J Clin Hypertens (Greenwich). 2007;9:937943.
  • 4
    Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:19571963.
  • 5
    Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47:345351.
  • 6
    Basile J. The importance of prompt blood pressure control. J Clin Hypertens (Greenwich). 2008;10(suppl 1):1319.
  • 7
    Mancia G, De Backer G, Dominiczak A, et al; for the Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:11051187.
  • 8
    Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. J Clin Hypertens (Greenwich). 2002;4:393404.
  • 9
    Julius S, Kjeldsen E, Weber MA, et al. Outcomes in hypertensive patients at high cardiovascular risk treatment with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:20222031.
  • 10
    Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:20492051.
  • 11
    Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled study. ASCOT investigators. Lancet. 2005;366:895906.
  • 12
    Neutel JM, Franklin SS, Oparil S, et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich). 2006;8:850857.
  • 13
    Neutel JM, Franklin SS, Lapuerta P, et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens. 2008;22:266274.
  • 14
    Jamerson K, Bakris GL, Dahlöf B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16:8086.
  • 15
    Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:18871898.
  • 16
    Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:21212158.
  • 17
    Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:14271431.
  • 18
    Weir MR, Levy D, Crikelair N, et al. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens. 2007;20:807815.
  • 19
    Neutel JM, Saunders E, Bakris GL, et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005;7:578586.
  • 20
    Cappuccio FP, Kerry SM, Forbes L, et al. Blood pressure control by home monitoring: meta-analysis of randomized trials. BMJ. 2004;329:493499.
  • 21
    Staessen JF, Hond ED, Celis H, et al. Antihypertensive treatment based on blood pressure measurement at home or in the physician’s office. A randomized control trial. JAMA. 2004;291:955964.
  • 22
    Mallion JM, Genes N, Vaur L, et al. Detection of masked hypertension by home blood pressure measurement: is the number of measurements an important issue? Blood Press Monit. 2004;9:301305.
  • 23
    Obara T, Ohkubo T, Kikuya M, et al. Prevalence of masked uncontrolled and treated white-coat hypertension defined according to the average of morning and evening home blood pressure value: from the Japan Home versus Office Measurement Evaluation Study. Blood Press Monit. 2005;10:311316.
  • 24
    Kabutoya T, Ishikawa J, Hoshide S, et al. A home blood pressure monitor equipped with a graphic function facilitates faster blood pressure control than the conventional home blood pressure monitor. J Clin Hypertens (Greenwich). 2009;11:422425.
  • 25
    Casalino L. The unintended consequences of measuring quality on the quality of medical care. N Engl J Med. 1999;341:11471150.
  • 26
    Hayward RA. All or nothing treatment targets make bad performance measures. Am J Managed Care. 2007;13:126128.